Loading quotes...
Forecast
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2021 | YoY |
|---|---|---|
| Revenue | 1.44M | 29.32% |
| Gross profit | 1.44M | 29.32% |
| Net profit | -13.56M | 62.22% |
| EBITDA | -14.55M | 57.00% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €0 |
52-week high/low | €1.32 - €0.0000908 |
| Dividends | No |
Beta | 0.00 |
P/E ratio | 0.00 |
PEG ratio | 0.00 |
P/B ratio | 0.00 |
P/S ratio | 0.00 |
Company profile
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
| Name | Genocea Biosciences |
| CEO | William Clark |
| Headquarters | Cambridge,
ma USA |
| Website | |
| Sector | Consumer Staples |
| Industry | Food Products |
| IPO | 02/05/2014 |
| Employees | 74 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | GNCA |
London | 0A51.L |